Gaucher disease type 2

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:77260OMIM:230900E75.2
Who is this for?
Show terms as
31Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Gaucher disease type 2, also called acute neuronopathic Gaucher disease or infantile cerebral Gaucher disease, is a very rare and severe inherited condition. It belongs to a group of diseases called lysosomal storage disorders. In Gaucher disease type 2, the body does not make enough of an enzyme called glucocerebrosidase. This enzyme is responsible for breaking down a fatty substance called glucocerebroside. Without enough of this enzyme, the fatty substance builds up inside cells throughout the body, especially in the brain, liver, spleen, and bone marrow. This buildup causes serious damage to many organs, but the brain damage is the most severe part of this condition. Babies with Gaucher disease type 2 usually appear healthy at birth but begin showing symptoms within the first few months of life. The brain and nervous system are severely affected, leading to problems with movement, swallowing, and breathing. The liver and spleen also become very enlarged. Unlike other types of Gaucher disease, the neurological damage in type 2 progresses very rapidly and cannot be stopped with currently available treatments. There is currently no cure for Gaucher disease type 2. Enzyme replacement therapy, which works well for type 1 Gaucher disease, does not cross into the brain and therefore cannot treat the neurological symptoms. Care is focused on keeping the baby as comfortable as possible and supporting the family. Research into new treatments, including gene therapy and substrate reduction therapy, is ongoing but has not yet produced an effective option for this form of the disease.

Also known as:

Key symptoms:

Enlarged liver and spleen (belly looks swollen or feels hard)Severe brain and nervous system damageMuscle stiffness or spasmsDifficulty swallowingBreathing problemsAbnormal eye movements (eyes move in unusual ways)SeizuresLoss of previously gained developmental skillsFailure to thrive or poor weight gainExtreme muscle weakness or floppinessSkin may appear yellowish (jaundice) in some casesAnemia (low red blood cells, causing paleness and tiredness)

Clinical phenotype terms (33)— hover any for plain English
Abnormal pattern of respirationHP:0002793TrismusHP:0000211Supranuclear gaze palsyHP:0000605
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

9 events
Aug 2025Combination Immunotherapy Targeting Melanoma

Shenzhen Geno-Immune Medical Institute — PHASE1, PHASE2

TrialRECRUITING
May 2025Study on GD2 Positive Solid Tumors by 4SCAR-GD2

Shenzhen Geno-Immune Medical Institute — PHASE1, PHASE2

TrialRECRUITING
Mar 2025International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma

Prof. Dr. Dirk Reinhardt — PHASE1

TrialNOT YET RECRUITING
Nov 2024Anti-GD2 ADC M3554 in Advanced Solid Tumors

EMD Serono Research & Development Institute, Inc. — PHASE1

TrialRECRUITING
Apr 2024Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Margaret Gatti-Mays — PHASE1, PHASE2

TrialRECRUITING
Jun 2023Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

UNC Lineberger Comprehensive Cancer Center — EARLY_PHASE1

TrialRECRUITING
Jun 2022GD2/CD70 Bi-specific CAR-T Cell Therapy

Shenzhen Geno-Immune Medical Institute — PHASE1, PHASE2

TrialRECRUITING
Jun 2022GD2/PSMA Bi-specific CAR-T Cell Therapy

Shenzhen Geno-Immune Medical Institute — PHASE1, PHASE2

TrialRECRUITING
Jun 2022GD2/CD56 Bi-specific CAR-T Cell Therapy

Shenzhen Geno-Immune Medical Institute — PHASE1, PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Gaucher disease type 2.

View clinical trials →

No actively recruiting trials found for Gaucher disease type 2 at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Gaucher disease type 2 community →

Specialists

Showing 25 of 31View all specialists →
AG
Andrew Gilman
Specialist
PI on 1 active trial
MB
Marion M Brands
Specialist
1 Gaucher disease type 2 publication
ES
Eleonora L Swart
Specialist
1 Gaucher disease type 2 publication
HB
Hennie Bikker
Specialist
1 Gaucher disease type 2 publication
CH
Carla E M Hollak
Specialist
1 Gaucher disease type 2 publication
BH
Bénédicte Héron
Specialist
1 Gaucher disease type 2 publication
MR
Marianne Rohrbach
Specialist
1 Gaucher disease type 2 publication
MG
Matthias Gautschi
Specialist
1 Gaucher disease type 2 publication
MP
Marc Patterson
Specialist
1 Gaucher disease type 2 publication
BH
Bibiche den Hollander
Specialist
1 Gaucher disease type 2 publication
HL
Hoang Lan Le
Specialist
1 Gaucher disease type 2 publication
SM
Sara M. Federico, MD
MEMPHIS, TN
Specialist
PI on 3 active trials
SP
Svetlana Kulyova, MD, Phd
Specialist
PI on 1 active trial
BM
Brian Kushner, MD
NEW YORK, NY
Specialist
PI on 8 active trials
RM
Rosandra N Kaplan, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 4 active trials
SM
Sara Federico, MD
MEMPHIS, TN
Specialist
PI on 4 active trials
EM
Edward Kaye, M.D.
CAMBRIDGE, MA
Specialist
PI on 1 active trial
EM
Eugen Mengel
Specialist
1 Gaucher disease type 2 publication
CK
Chrysoula Kosmeri
Specialist
1 Gaucher disease type 2 publication
BS
Barbara Schwierin
Specialist
1 Gaucher disease type 2 publication
LT
Luba Trokan
Specialist
1 Gaucher disease type 2 publication
PC
Peter Cornelisse
Specialist
1 Gaucher disease type 2 publication
MM
Michelle Monje
PALO ALTO, CA
Specialist
PI on 1 active trial
LC
Lung-Ji Chang
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Gaucher disease type 2.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Gaucher disease type 2Forum →

No community posts yet. Be the first to share your experience with Gaucher disease type 2.

Start the conversation →

Latest news about Gaucher disease type 2

Disease timeline:

New recruiting trial: Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

A new clinical trial is recruiting patients for Gaucher disease type 2

New recruiting trial: Combination Immunotherapy Targeting Melanoma

A new clinical trial is recruiting patients for Gaucher disease type 2

New recruiting trial: GD2/CD56 Bi-specific CAR-T Cell Therapy

A new clinical trial is recruiting patients for Gaucher disease type 2

New recruiting trial: Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma

A new clinical trial is recruiting patients for Gaucher disease type 2

New recruiting trial: GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

A new clinical trial is recruiting patients for Gaucher disease type 2

New recruiting trial: GD2/PSMA Bi-specific CAR-T Cell Therapy

A new clinical trial is recruiting patients for Gaucher disease type 2

New recruiting trial: Anti-GD2 ADC M3554 in Advanced Solid Tumors

A new clinical trial is recruiting patients for Gaucher disease type 2

New recruiting trial: Study on GD2 Positive Solid Tumors by 4SCAR-GD2

A new clinical trial is recruiting patients for Gaucher disease type 2

New recruiting trial: CAR T Cells to Target GD2 for DMG

A new clinical trial is recruiting patients for Gaucher disease type 2

New recruiting trial: GD2/CD70 Bi-specific CAR-T Cell Therapy

A new clinical trial is recruiting patients for Gaucher disease type 2

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What specific mutations were found in my child's GBA1 gene, and what do they mean for the disease course?,Will enzyme replacement therapy help my child, and what symptoms can it realistically improve?,Are there any clinical trials or experimental treatments available that we should consider?,When should we involve a palliative care team, and what does palliative care look like for this condition?,What signs should prompt us to go to the emergency room immediately?,What support services — such as home nursing, respite care, or counseling — are available to our family?,What are the chances that future children we have could also be affected, and what prenatal testing options exist?

Common questions about Gaucher disease type 2

What is Gaucher disease type 2?

Gaucher disease type 2, also called acute neuronopathic Gaucher disease or infantile cerebral Gaucher disease, is a very rare and severe inherited condition. It belongs to a group of diseases called lysosomal storage disorders. In Gaucher disease type 2, the body does not make enough of an enzyme called glucocerebrosidase. This enzyme is responsible for breaking down a fatty substance called glucocerebroside. Without enough of this enzyme, the fatty substance builds up inside cells throughout the body, especially in the brain, liver, spleen, and bone marrow. This buildup causes serious damage

How is Gaucher disease type 2 inherited?

Gaucher disease type 2 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Gaucher disease type 2 typically begin?

Typical onset of Gaucher disease type 2 is infantile. Age of onset can vary across affected individuals.

Which specialists treat Gaucher disease type 2?

25 specialists and care centers treating Gaucher disease type 2 are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.